Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference

to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference

LAKE CITY, June 14, 2023 - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System

(CNS) disorders by leveraging its proprietary platform to develop differentiated products, today announced that Dr. Mahesh Patel, President

and Chief Executive Officer, will present virtually and meet with investors at the H.C. Wainwright 4th Annual Neuropsychiatry

Virtual Conference on June 26, 2023.

webcast link will be available for 90 days.

can register for the conference here. Those interested in arranging a 1x1 meeting with Lipocine should contact their H.C. Wainwright

is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery

to develop products for CNS disorders. Lipocine has drug candidates in development as well as drug candidates for which we are exploring

partnering. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit

to risk profile which target large addressable markets with significant unmet medical needs.

clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101

for the potential treatment of epilepsy and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for

the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate

for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated

cirrhosis, LPCN 1144, our candidate for treatment of non-cirrhotic NASH, and LPCN 1111, a once-a-day therapy candidate for testosterone

replacement therapy (TRT). TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is

approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males.

For more information, please visit www.lipocine.com.

release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities

Litigation Reform Act of 1995 and include statements that are not historical facts regarding our product development efforts, the application

of our proprietary platform in developing new treatments for CNS disorders, our product candidates and related clinical trials, and the

potential uses and benefits of our product candidates. Investors are cautioned that all such forward-looking statements involve risks

and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates to treat CNS

disorders, we may not have sufficient capital to complete the development processes for our product candidates, we may not be able to

enter into partnerships or other strategic relationships to monetize our non-core assets, the FDA will not approve any of our products,

risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being

realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory

approvals and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, patient

acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed

in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of

which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking

statements contained in this release, except as required by law.

further information: